summaryThe present study was undertaken to explore the role of nitric oxide (NO) in the pathogenesis of experimental non-steroidal anti-inflammatory drug (NSAID)-induced gastropathy. We assessed the role of NO inhibition and donation in indomethacin-induced gastric mucosal dysfunction. The stomach was perfused with vehicle (control) for 20 min, followed by indomethacin (10 mg ml¢ in 1·25% sodium bicarbonate, pH 8·4) for 120 min. N G -nitro-¬_arginine methyl ester (¬_NAME, 5 and 10 mg kg¢, i.v. bolus), ¬_arginine, ª_arginine (100 mg kg¢ i.v. bolus, 10 mg kg¢ h¢, 2 h infusion) and the NO donor glyceryl trinitrate (GTN) were given at the same time (20, 40 and 80 ìg kg¢ min¢, 15 min infusion) as perfusion with indomethacin was started. Epithelial permeability was quantified by measuring blood-to-lumen clearance of 51 Cr-labelled EDTA. Indomethacin caused a 20-fold increase in 51 Cr-EDTA leakage compared with that of the control group. Treatment with ¬_NAME or ¬_arginine did not affect the indomethacin-induced alterations in mucosal permeability. Administration of GTN (20 ìg kg¢ min¢) significantly reduced the indomethacin-induced mucosal dysfunction. By contrast, higher doses of GTN (80 ìg kg¢ min¢) exacerbated epithelial dysfunction induced by indomethacin. Elevated levels of carbonyls and myeloperoxidase (MPO) observed after indomethacin administration were significantly reduced, to the control values, when GTN (20 ìg kg¢ min¢) was administered along with indomethacin.